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1144 The Journal of Thoracic and CardBackground: Aspiration of gastroesophageal refluxate may contribute to lung trans-
plant bronchiolitis obliterans syndrome (BOS). We investigated bile acids in bron-
choalveolar lavage fluid (BALF) and studied its role in BOS.
Materials and Methods: Surveillance pulmonary function tests and BALF were
evaluated in 120 lung recipients. BOS-(0p-3) was diagnosed after 6 months’
survival. BOS was defined as “early” if diagnosed within 12 months after a
transplant. BALF was assayed for differential cell count, bile acids, and interleukins
8 and 15. Bile acids were considered elevated if greater than normal serum levels
(8 mol/L).
Results: Elevated BALF bile acids were measured in 20 (17%) of 120 patients. BOS
was diagnosed in 36 (34%) of 107 patients and judged “early” in 21 (57%) of 36.
Median BALF bile acid values were 1.6 mol/L (range, 0-32 mol/L) in BOS
patients and 0.3 mol/L (range, 0-16 mol/L) in non-BOS patients (P  .002); 2.6
mol/L (range, 0-32 mol/L) in early BOS patients and 0.8 mol/L (range, 0-4.6
mol/L) in late BOS patients, (P  .02). Bile acids correlated with BALF IL-8 and
alveolar neutrophilia (r  0.3, P  .0004, and r  0.3, P  .004, respectively), but
not with IL-15. Freedom from BOS was significantly shortened in patients with
elevated BALF bile acids (Cox-Mantel test, P  .0001).
Conclusions: Aspiration of duodenogastroesophageal refluxate is prevalent after
lung transplantation and is associated with the development of BOS. Elevated
BALF bile acids may promote early BOS development via an inflammatory process,
possibly mediated by IL-8 and alveolar neutrophilia.
Lung transplantation is effective therapy for patients with a variety of end-stage lung diseases, although the development of posttransplant bronchiolitisobliterans is the major limitation to the long-term success of lung transplan-
tation. Bronchiolitis obliterans (ie, a process of obliteration of the small airways and
its clinical correlate) and bronchiolitis obliterans syndrome (BOS; identified as a
persistent drop in the forced expiratory volume in 1 second after transplantation) are
progressive, respond poorly to augmented immunosuppression, and account for
more than 30% of all deaths occurring after the third postoperative year.1,2
Alloimmune-mediated injury directed against endothelial and epithelial structures
has been thought to be the underlying cause of bronchiolitis obliterans; however
nonalloimmunologic inflammation, including viral infections or ischemic injury,
appear also to play a role.3 Among the possible inflammatory conditions, aspiration
secondary to gastroesophageal reflux (GER) has been suggested to be a potential
contributor to lung allograft dysfunction and, in particular, to the development of
bronchiolitis obliterans.4,5
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TXGER disease may be promoted after lung transplantation
due to the potential for iatrogenic vagal nerve injury during
the course of lung transplantation and to the use of immu-
nosuppressive drugs such as calcineurin inhibitors (cyclo-
sporine and tacrolimus) that cause prolongation of gastric
emptying.4-6
The association between lung disease and GER disease
has been recognized for a long time.7,8 In fact GER has been
documented to be highly prevalent in patients with a variety
of lung diseases: in particular, patients with asthma, cystic
fibrosis, and idiopathic pulmonary fibrosis.9,10 Furthermore,
GER disease has been also associated with the development
of bronchiolitis obliterans with organizing pneumonia.11
Several methods to document the relationship between lung
disease and GER disease have been studied, including scin-
tigraphic monitoring, 24-hour esophageal pH testing, and
assays for pepsin in saliva and sputum.12,13 A possible role
of duodeno-GER has also been investigated postmortem in
sudden infant death syndrome by testing for bile acids
within the bronchoalveolar district.14 The potential for a
role for duodeno-GER is significant in the context of lung
transplantation, which is characterized by a high incidence
of reduced foregut peristalsis.4 We therefore sought to in-
vestigate the role of aspiration in this setting by assaying
bile acids in bronchoalveolar lavage fluid (BALF) collected
during surveillance bronchoscopies and by studying the role
of bile acids in the development of BOS. We also studied
the relationship between the presence of bile acids within
the bronchoalveolar district and other markers that have
been associated with the development of BOS. Specifically,
we studied the relationship between bile acids and alveolar
neutrophilia and interleukin 8 (IL-8) within the BALF.15,16
We also studied the interaction with interleukin 15 (IL-15)
in an attempt to examine for a possible stimulatory effect of
the innate and adaptive immune systems secondary to the
presence of bile acids within the bronchoalveolar district.17
Material and Methods
Starting from January 2003, clinical information and excess bio-
logical samples (BALF and serum samples) from routine fol-
low-up testing have been collected in 120 lung transplant recipi-
ents. BALF was collected from the right middle lobe in bilateral lung
transplants and from the right middle lobe or the lingula for single
transplants, while transbronchial biopsies (TBBx) were taken from the
right upper and right lower lobes in bilateral lung transplants and from
the upper and lower lobes in the single lung transplants.
Bronchoscopies with BALF collection and TBBx are routinely
performed in the Toronto Lung Transplant Program at 2 and 6
weeks after transplantation, every 3 months for the first year, every
6 months for the second year, and thereafter, as clinically indi-
cated. Thus, data were collected prospectively from consecutive
lung transplant patients, although data were also collected from
patients who underwent bronchoscopies for diagnostic purposes.
Data were collected regarding BOS development by routine
pulmonary function tests. BOS status was determined according to 
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ing criteria3: BOS-0, absence of the syndrome; BOS-0p-3, pres-
ence of 1 of the 4 grades of the syndrome.
For the purpose of this study, patients were required to have
been out from transplant at least 6 months before the calculation of
the BOS grade and were classified according to the presence or
absence of the syndrome; furthermore, the interval of time from
transplant to development of BOS was calculated and quantified in
months. The time interval from transplant to BOS development
was defined as “early” or “late,” according to whether BOS-(0p-3)
occurred within 12 months of the transplant or not.
The BALF was sent for differential cell count with relative
percentage calculation and for microbiology testing. Microbiologic
information on the presence or absence of positive bacterial, fun-
gal, or viral cultures was also collected.
The TBBx were assessed for acute rejection and graded ac-
cording to the Lung Rejection Study Group revised criteria.18 The
samples were evaluated for presence or absence and grade of
rejection and for the presence or absence of signs of inflammation
other than acute rejection.
Aliquots of the BALF, taken from the right middle lobe from
bilateral and right single lung transplants and from the lingula for
left single transplants, were also collected and snap frozen at
80°C. The samples were thawed and protease inhibitors (Com-
plete Mini tabs; Boehringer-Mannheim, Mannheim, Germany)
were added; the samples were then clarified by centrifugation at
5,000g for 10 minutes. The resulting supernatant was assayed for
bile acids. The samples were also tested for interleukins 8 (IL-8)
and 15 (IL-15) by ELISA with the use of the antibody paired kits
(CytoSet kit; BioSource International, Inc, Camarillo, Calif).
To examine the correlation between BALF and serum bile
acids, we tested their levels in serum samples (n 30 patients)
collected within 24 hours of the BALF samples.
The protocol was approved by the Research Ethics Board of the
Toronto General Hospital, University Health Network, and in-
formed consent was obtained from each patient for the use of
excess BALF and serum, in adherence to the principles set forth in
the Helsinki declaration.
Bile Acid Assay
The bile acid determination in BALF and serum was per-
formed with a spectrophotometric enzymatic assay. The
assay was conducted according to the kit instructions
(Sigma Diagnostics, Inc, St Louis, Mo). BALF bile acids
levels were considered high when they were greater than
normal serum levels, (8 mol/L), low if they were be-
tween 0 to 8, and absent when they were equal to 0.
Inasmuch as there is no accepted “normal” level of bile acid
in BALF, we arbitrarily chose 8 mol/L (serum upper limit
of the normal level range) as a conservative “upper limit of
normal.”
Statistics
Statistical analysis was performed with the use of StatView
5 software (StatView, SAS Institute Inc, Cary, NC). Non-
parametric statistical analysis of correlation was performed
by the Spearman rank correlation test. The Kruskal-Wallis
and Cardiovascular Surgery ● Volume 129, Number 5 1145
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comparison of continuous variables between groups. Cate-
gorical data were analyzed by the 2 test or the Fisher exact
test. Nonparametric actuarial curves, along with the
Breslow-Gehan-Wilcoxon test and the Cox-Mantel log-rank
test, were used to test the differences in patients grouped
with respect to BALF bile acids levels with regard to
freedom from BOS-(0p-3) development and with regard to
post–lung transplant survival.
Results
To date, 107 of 120 patients have been assessed with regard
to their BOS status, and BOS-(0p-3) was diagnosed in 36
(34%) of 107 patients: 5 patients with BOS-0p; 14 with
BOS-1; 8 with BOS-2; and 9 with BOS-3. The median
follow-up times were 14 months (range, 6-46 months) for
the patients free of BOS and 24 months (range, 6-125
months) for those with a diagnosis of BOS-(0p-3). Among
the 36 patients with a diagnosis of BOS-(0p-3), the syn-
drome had developed within 12 months of the transplant in
21 patients and was judged “early onset”; in 15 it had
developed “late” (after 12 months). The median follow-up
time was 18 months (range, 6-40 months) and 36 months
(range, 20-125 months) in the early and late groups, respec-
tively, while the median interval of time from transplant to
BOS diagnosis was 6.5 months (range, 2-12 months) and 28
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Figure 1. The BALF total bile acids quantified in patient
acid level was 0.3 mol/L (range, 0-16 mol/L) for th
BOS-(0p-3) group (P  .002). In a stratification of the B
late (>12 months) BOS development, total bile acids
(range, 0-4.6 mol/L), respectively (P  .02). The box pl
the 10th and 90th percentile.months (range, 13-108 months), respectively.
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from transplant and who underwent bronchoscopy, 250
BALF samples were collected. For each parameter studied,
namely total bile acids, IL-8 and IL-15, and the differential
cell count, the average of the result obtained from the BALF
samples of each patient was used as a single value for that
patient for the purpose of statistical analysis.
Patients with BOS-(0p-3) status had significantly higher
levels of IL-8 (median, 121 pg/mL; range, 0.1-358 pg/mL)
and IL-15 (median, 26.2 pg/mL; range, 0-109 pg/mL), com-
pared with patients with a BOS-0 status (IL-8: median, 64.5
pg/mL; range, 0-381; IL-15: median, 15.6 pg/mL; range,
0-615 pg/mL), P  .0006 and P  .04, respectively. Com-
parison between patients with early BOS-(0p-3) and those
with late development showed no significant difference for
IL-8. In contrast, there were significantly higher levels of
IL-15 (median, 39 pg/mL; range, 0-109 pg/mL) in the late
development group versus the early group (median, 19
pg/mL; range, 0-101 pg/mL), P  .04.
No correlation between the time points of the BALF
collection and those of the IL-8 and IL-15 was noted in all
samples (r  0.2 and r  0.1, respectively; Spearman rank
correlation test), although a significant correlation was
noted for IL-15 in samples from BOS patients (r 0.4, P
.0008).
No difference was noted for the BALF differential cell
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TXparing either BOS-0 to BOS-(0p-3) patients or early versus
late BOS-(0p-3) development patients.
The total bile acids quantified in BALF and in serum
samples in 30 patients with concurrent collection of the
samples showed no correlation (r  0.067; Spearman rank
correlation test). Therefore, the presence of bile acids within
the bronchoalveolar district is not likely due to serum but
rather from retrograde aspiration of duodeno-GER.
The average levels of bile acids quantified within the
BALF were found to be high (8 mol/L) in 10/107 (9.3%)
patients, low (greater than 0 and less than 8) in 61 (57%) of
107 patients. In 36 (34%) of 107 patients, no bile was
detected in the BALF.
No correlation between the time points of the BAL
collection and the bile acids levels was noted (r  0.04;
Spearman rank correlation test).
Patients with BOS-(0p-3) had significantly higher bile
acids within their BALF than did patients with BOS-0 status
(Figure 1). Moreover, as shown in Figure 1, patients in
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Figure 2. Bile acid within the BALF showed a significa
noted for IL-15. The median IL-8 was 118 pg/mL (range,
(range, 0-381 pg/mL) for patients with low BALF bile ac
bile acids (P .01, Kruskal-Wallis; Mann-Whitney test
bile group showed a P .02 and P .01 respectively).
bile acids group, 21 pg/mL (range, 0-615 pg/mL) for the
the no bile acid group (P  .4, Kruskal-Wallis test). B
the relative neutrophil cell count but no relationship to
levels, the median neutrophils were 2% (range, 0%-27%
0%-34%) in the group with low BALF bile acids; and 5%
 .015, Kruskal-Wallis test; Mann-Whitney test for com
and no bile acids groups showed a P  .007 and P 
(range, 0%-18%) for the no bile acid group, 1.5% (range,
0%-3%) in the high bile acid group (P  .7, Kruskal-Wa
and the bars, the 10th and 90th percentile.whom BOS-(0p-3) developed early had significantly greater
The Journal of Thoracicbile acid quantities within the BALF than did the patients in
whom BOS developed late. Of the patients with high BALF
bile acids, 7 (70%) of 10 were BOS-(0p-3), and all had the
syndrome within the first 12 months from transplant.
A significantly greater quantity of IL-8 was measured in
patients with high levels of bile acids within the BALF,
compared with patients with low or absent bile acids. In
contrast, no difference was noted with regard to the quan-
tities of IL-15 between the groups, as shown in Figure 2.
Patients with high levels of bile acids also had a greater
number of alveolar neutrophils than did patients with low
bile acids. No difference was noted in the number of alve-
olar lymphocytes among the groups, as shown in Figure 2.
Analysis of the relationship between bile acids, alveolar
neutrophils, IL-8, and IL-15 revealed a moderate correlation
between bile acids and alveolar neutrophilia (r  0.3; P 
.005) and IL-8 (r  0.35; P  .0004). The correlation for
IL-8 also exists in patients with early development of the
syndrome (r  0.5; P  .03). No correlation was observed
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TXOf the total cohort of patients, 93 of 107 were consecu-
tive patients undergoing lung transplants who survived
more than 6 months. In 85 patients, the BALF was collected
prospectively before the diagnosis of BOS-(0p-3). BOS-
(0p-3) was subsequently diagnosed in 15 (18%) of 85 dur-
ing the course of this study: 1 patient with BOS-0p; 5 with
BOS-1; 4 with BOS-2; and 5 with BOS-3. The median
follow-up time was 14 months (range, 6-29 months) for the
patients free of BOS and 14 months (range, 6-22 months)
for those with a diagnosis of BOS-(0p-3). In the latter
group, the median interval of time from transplant to BOS-
(0p-3) diagnosis was 9 months (range, 3-16 months).
The time to BOS-(0p-3) development from the transplant
was quantified in months and used to determine the actuarial
freedom from BOS development; the 85 patients with pro-
spective data collection were grouped according to levels of
bile acids (Figure 3). The curves were generated from the
data pertaining to the cohort of 85 patients in which the
BALF fluid samples were collected prospectively from the
time of transplant. In the BOS-(0p-3) patients, only bile acid
quantification results from BALF samples collected before
BOS development were used for the analysis. Of these 85
patients, 33 did not have any bile acid detected in the BALF,
43 patients had a total bile acid concentration between 0 to
8 mol/L, and 9 patients had bile acid readings greater than
or equal to 8 mol/L.
From the 120 patients, 272 BALF samples were studied.
Of these, 261 had microbiology reports. Of all the concom-
itant transbronchial biopsies performed, 184 of 272 were
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1148 The Journal of Thoracic and Cardiovascular Surgery ● Maacute rejection, and 203 were adequate for determination of
signs of inflammation. In BALF samples grouped with
regard to the presence or absence of signs of inflammation
in the concomitant TBBx, samples with inflammation
showed a median 1.1 mol/L bile acids (range, 0-54 mol/
L), and samples negative for inflammation showed a median
0.2 mol/L of bile acids (range, 0-71 mol/L), P  .007.
When the samples were grouped for the presence or absence
of acute rejection diagnosed from concomitant TBBx, no
difference was noted.
BALF samples grouped according to microbiology cul-
ture findings showed a significantly greater quantity of bile
acids in BALF samples positive for bacterial growth (me-
dian, 0.7 mol/L; range, 0-71 mol/L) than in the samples
negative for bacteria (median, 0.3 mol/L; range, 0-52
mol/L; P  .02). Similarly, bile acid quantities were
significantly greater in samples positive for fungal growth
(median, 0.75 mol/L; range, 0-57 mol/L) than in the
samples negative for fungus (median, 0.36 mol/L; range,
0-71 mol/L; P  .048). No significant association was
seen in relation to the presence of cytomegalovirus in the
BALF.
Discussion
Over the past decade, improvements in surgical techniques,
lung preservation, immunosuppression, and management of
ischemia–reperfusion injury and infections have contributed
to an increase in the 1-year patient survival after lung
transplantation to 70% to 80%.19 However, long-term sur-
gh bile acids
5 30
Figure 3. Interval from transplant to devel-
opment of BOS-(0p-3). The actuarial curves
show a significantly reduced interval of time
from transplant to BOS-(0p-3) development in
patients with high BALF bile acids levels.
Breslow-Gehan-Wilcoxon test and Cox-
Mantel log-rank test showed P  .007 and P
 .002, respectively, for the comparison be-
tween the group with low bile levels and the
group with high bile levels; P  .0001 for
both tests for the comparison between the
group with no detection of bile acids and the
group with the high levels of bile acids
within the BALF; and P  .1 for the compar-
ison between the group with no BALF bile
acids and the group with low BALF bile acid
levels.Hi
2vival continues to be threatened by the development of
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clinical correlate, BOS was identified as a persistent drop in
the forced expiratory volume in 1 second after transplanta-
tion, which affects 50% to 60% of patients at 5 years after
transplantation.2
Five-year survival after the onset of bronchiolitis oblit-
erans is only 30% to 40%, and survival at 5 years after
transplantation is 20% to 40% lower in patients with bron-
chiolitis obliterans.20
Acute and chronic onset of BOS has been described,
suggesting that BOS reflects at least 2 modes of onset with
different natural histories.21 Interestingly, 2 forms of bron-
chiolitis obliterans have been described in heart-lung trans-
plant recipients: a relatively acellular concentric fibrosing
process limited to the terminal bronchioles; and a focal and
cellular process extending into the distal alveolar spaces,
and associated with aspirated material and foreign body–
type giant cells.22 The latter pathologic finding is indeed
supportive of a possible role for GER in the development of
bronchiolitis obliterans.4,5
A possible role of retrograde aspiration after GER in the
early development type of BOS has been implicitly docu-
mented in the recent work from Cantu and colleagues,23 in
which they show that, in lung transplant patients with
known GER disease, early fundoplication led to significant
improvements in freedom from the development of BOS.
GER disease has been also associated with the develop-
ment of bronchiolitis obliterans–associated pneumonia or
diffuse bronchiolitis in the non–lung transplant popula-
tion.11,24
In lung transplant patients, pulmonary defense mecha-
nisms, including the cough reflex and mucociliary clearance
of foreign bodies, are markedly impaired. Mucociliary
clearance has been measured to be less than 15% of normal
in transplanted lungs.4 It is conceivable that a prolonged
contact time of aspirated gastric contents may therefore lead
to substantially greater lung parenchymal injury. Moreover,
while GER may cause direct lung injury, it is also possible
that it may play a role in augmenting the alloimmune
response by creating an upregulated inflammatory milieu
locally.5
Bile aspiration secondary to duodeno-GER has been
associated with severe pulmonary injury25 and the cytotox-
icity may result in the disruption of the cellular membrane
or in the alteration of cellular cationic permeability depend-
ing on the bile acid concentration, as Oleberg and col-
leagues26 demonstrated in vitro using type II pneumocytes.
The potential for a significant role for aspiration second-
ary to duodeno-GER is prominent in the context of lung
transplantation, which is characterized by a high incidence
of reduced foregut peristalsis.4 Moreover, chronic silent
acid aspiration per se may not be as injurious as aspiration
of other components of the refluxate.27 We have attempted
The Journal of Thoracicto objectively investigate aspiration by assessing for pres-
ence of bile acids in BALF collected during surveillance
bronchoscopies and have studied its potential contribution
to the development of BOS. Bile acids were investigated as
markers of duodeno-GER, rather than as a causative agent
of the refluxate. Other components of the duodenal and
gastric juices, such as pepsin and trypsin, could be impli-
cated, as long as one considers that the bronchoalveolar
district has a pH that favors the activity of the duodenopan-
creatic agents, rather than the gastric ones.
One would intuitively expect that no bile acids would be
detectable in the lung under normal conditions. However,
the levels of bile acids in vivo within the bronchoalveolar
district have not been previously reported; thus, no levels of
normality have been determined. We therefore chose to use
the upper limit of normal for serum bile acids (8 mol/L)
as “normal” for the purpose of this study.
On examining BALF and serum samples collected
within 24 hours of the bronchoscopy, we noted no correla-
tion for quantities of total bile acids, suggesting that read-
ings within fluid collected from the bronchoalveolar district
is secondary to retrograde aspiration, rather than to serum
bile acid. We have also noted a relationship between BALF
bile acids and abnormal pH findings in lung transplant
patients.28
The data collected in our study clearly defined an early
and late BOS development group of patients with specific
biological characteristics, thus supporting the existence of 2
types of onset of BOS. There is a definite association
between reduced time to BOS development and levels of
bile acids detected within the bronchoalveolar district. The
early BOS patients in our study had a greater content of bile
acids within their BALF samples, compared to the late BOS
group. Of the patients with high BALF bile acids levels,
70% had BOS-(0p-3), and in all the syndrome had devel-
oped within the first 12 months from surgery. Table 1 shows
the distribution of the patients according to the level of bile
acids and BOS grade, and according to the time to devel-
Table 1. Distribution frequency of patients grouped ac-
cording to bile acids levels and the presence or absence of
BOS-(0p-3), and according to early versus late develop-
ment of BOS-(0p-3) (P  .009 and P  .02, respectively; 2
test)
BOS and BALF bile acid association
BOS-0 BOS-(0p-3) Total Early Late Total
No bile acids 29 7 36 2 5 7
Low bile acids 39 22 61 12 10 22
High bile acids 3 7 10 7 0 7
Total 71 36 107 21 15 36opment of BOS.
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tribute to lung graft dysfunction appears to be mediated by
IL-8 and alveolar neutrophilia. Interestingly, both Il-8 and
alveolar neutrophilia have been previously described as
putative clinical markers of BOS development.15,16 More-
over, in patients with early BOS development, the relation-
ship between bile acids and IL-8 seems to be particularly
strong.
Interestingly, the late BOS group was found to have a
significantly greater content of IL-15. IL-15 is involved in
both innate and adaptive immunity with specific activity
toward lymphocyte proliferation. IL-15 also functions as an
antigen-independent activator of CD8 memory T cells,
which implies a possible different immunologic mechanism
involved in late versus early BOS development.17
The mechanism by which bile acids might contribute to
lung graft dysfunction was not the primary focus of this
study, although some hypotheses could be generated by the
significant association within the BALF between bile acid
and bacterial and fungal infection, and between the presence
of bile acids and the TBBx findings related to the diagnosis
of acute interstitial inflammation.
Bile acids act as barrier breakers within other organs,
such as the gastric mucosa, where they are known to disrupt
the surfactant layer that protects the mucosa.29,30 In a sim-
ilar fashion, this may well be happening within the bron-
choalveolar district with bile acids possibly functioning as
detergents to disrupt the lipid layers of the pulmonary
surfactant. Alternatively, bile acids may cause direct injury
to type II pneumocytes that are responsible for the produc-
tion and homeostasis of the pulmonary surfactant and its
related proteins.26 Thus, by disrupting locoregional innate
immunity, bile acids may consequentially promote infec-
tions and/or maintain chronic infections. Furthermore, they
could be responsible for upregulation of the adaptive im-
mune response, given that the 2 systems, innate and adap-
tive, are in a continuous balance adjustment. Thus, a loss of
effective innate immunity may lead to a more aggressive
adaptive immune response.31 Further studies are required to
validate these mechanistic hypotheses.
Conclusion
Our findings strongly support a significant role for GER
disease in the development of BOS after lung transplanta-
tion. We have documented that lung transplant patients with
bile in their BALF as a marker of duodeno-GER aspiration
have a reduced freedom from BOS. Importantly, patients
with high levels of bile acids in the BALF develop BOS
earlier. Elevated bile acids in the BALF of these patients are
associated with elevated IL-8 levels and increased BALF
neutrophilia. BOS is a devastating syndrome that affects
lung transplant patients. Clearly, its pathogenesis is multi-
factorial. The data obtained from this study provide addi-
1150 The Journal of Thoracic and Cardiovascular Surgery ● Mational objective evidence implicating a contributory role of
duodeno-GER in the development of BOS. Bile acids were
investigated as markers of retrograde aspiration, although a
temporal link, along with a dose-response effect, was ob-
served with the development of BOS. Furthermore, bile
acids carry a plausible biological activity toward lung inju-
ry25,26,29,30; thus, this study provides information that also
supports their active role, whether primary or contributive to
other agents, toward the development of bronchiolitis ob-
literans.
We hope that further objective evidence such as this will
help us to determine which lung transplant patients might
benefit from antireflux therapy to prevent at least 1 compo-
nent of the ongoing injury to the transplanted lung.
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Discussion
Dr Yolonda Colson (Boston, Mass). Very nice. In terms of mech-
anism, do you think that the bile acids themselves are causing the
injury, do you think it’s a marker for other things in the reflux that
are causing it, or do you think it’s actually activating macrophages,
neutrophils, whatever, in the lungs to then lead on to the injury?
Dr D’Ovidio. As of now, we can consider it only as a marker,
although our working hypothesis is that bile acid per se or other
components of the refluxate are interacting within the bronchoal-
veolar district, in particular with surfactant. We have preliminary
data showing a significant association of bile acid and surfactant
proteins A and D and an association between bile acid and dis-
ruption of the phospholipid layers, in particular with a reduced
quantity of DPPC and PG and an elevation of sphingomyelin and
lysoPC, the primary ones which are tensoactive and the later ones
which are markers of inflammatory status. Bile acids are cytotox-
ic—we know that from the hepatobiliary literature—and are bar-
rier-breakers, therefore may function as the key players.
The Journal of ThoracicDr Raphael Bueno (Boston, Mass). That was a very nice talk.
It continues to support the thesis that reflux harms lung transplant
patients. I have a few questions. Do the patients who are at high
risk for BOS and have a high reflux have a particular disease that
you transplant them for, or are they all comers? I mean is it mostly
patients with idiopathic pulmonary fibrosis and cystic fibrosis who
have reflux?
Dr D’Ovidio. They are all comers, and, in a smaller cohort of
patients, we have pH testing results showing no difference with
regard to the incidence of pH-metry abnormalities within the
different end-stage lung disease for which they were transplanted.
Furthermore, in the same cohort of patients, we did gastric emp-
tying studies, and, in those, there was an average of about 78% of
prolonged gastric emptying for solids, which was equally distrib-
uted for restrictive rather than obstructive end-stage lung disease.
I think there is a posttransplant high incidence of gastroesophageal
reflux disease, and it’s in about 50% of our patients with regard to
pH-metry. There is a significant gastric emptying delay factor,
which is in over 70% of the patients. Now, whether all of these are
aspirating, probably not, and that’s why we tried to document
aspiration objectively by using bile acid as a marker.
Dr Bueno. Let me understand this. Your hypothesis is that bile
aspiration is a more sensitive test for future BOS than, for exam-
ple, pH manometry or symptoms of reflux?
Dr D’Ovidio. It may be more specific, because not all pH-
tested patients had elevated bile acids within the BALs. We noted
an association between the presence of high bile acid content in
BALs and abnormal proximal esophageal pH-metry, but not with
distal pH-metry abnormalities within the esophagus.
Dr D. Davis (Durham, NC). I’m going to take you in a different
direction, essentially the ones that have zero or have no bile in it.
Does that mean that we should be wrapping absolutely everybody?
I mean obviously we have had an interest in only those that had
pretty significant reflux by pH testing. Does this mean that we
really need to be shooting for zero and that everybody should be
wrapped at the time that they get a lung transplant?
Dr D’Ovidio. I’m not sure we should be aiming for zero,
because we don’t know what the normal values within the BAL
samples of a normal patient population should be. Certainly bile
acid is a marker. I’m not sure it’s the best marker of aspiration
from the gastric content. Maybe pepsin or trypsin might work out
better and have a greater correlation with even the distal pH
testing, rather than the proximal pH testing within the esophagus.
I think that maybe not all pH-abnormal patients should be
wrapped. Probably a good portion of the patients will react to
prokinetic agents and not necessarily need wrapped. But definitely
if we consider this a valid marker, we should be quite aggressive
in treating whatever we can, because there is, as I’ve shown, a
temporal link with the elevation of bile acid in the BALs and the
more aggressive and early development of BOS.
Dr Davis. Well, I guess that’s the question. What you’re
showing has nothing to do with what’s normal or abnormal. What
you’re showing or implicating is that any is bad and that we really
should not be looking at normality but we really should be looking
at creating almost a superphysiologic prevention.
Dr D’Ovidio. Well, I do not think we’re showing that any is
detrimental, because within that low group of patients there is a
range between 0 and 8, and I suspect that the true cutoff should be
and Cardiovascular Surgery ● Volume 129, Number 5 1151
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not tried to determine which would be a better cutoff by statistics.
Dr Davis. I thought your data on the zero, though, was under-
powered, but it looked significantly better than even your, quote/
unquote, “low.”
Dr D’Ovidio. True, but there are in our group of patients
samples with a range of 0 to 1 mol/L which had no BOS
development within the time frame we assessed them.
Dr Sandro Mattioli (Bologna, Italy). Eighty percent of bile
acids which reflux in the stomach are glycoconjugated acids,
which turn in protonated form in an acid environment. In the
protonated form, bile acids have very low solubility and activity.1152 The Journal of Thoracic and Cardiovascular Surgery ● Mabile acids are in ionized, highly soluble, and active form .You were
correct when you said bile acids are at the present time mainly a
marker of reflux. We don’t’ know its pathologic mechanisms, if
there are any, when the stomach is normally secreting. So my
question is were those patients submitted to chronic acid sup-
pression therapy with proton pump inhibitors after transplanta-
tion in order to understand if they had an acid, acidic or alkaline
stomach.
Dr D’Ovidio. Postoperatively, all of our patients are on proton
pump inhibitors or H2-blockers. On the other hand, the bile acids
within the bronchoalveolar district would be in a nonacidic envi-
ronment. Therefore, they could change their presentation, and theyContrarily, in an acidic or alkaline environment, glycoconjugated may be activated.y 2005
